The Project<\/strong><\/p>\n The main challenge of biomarker commercialization is that while a lot of research identifying links between some biological signatures (Biomarkers) with diseases or response to the treatment, less than 2% will convert into clinical applicable diagnostic test (IVD Test). The discovery part is a substantial investment from research institutions, but the route to industrial development and to commercialisation is not part of the skills and expertise easily available in research institutions, even when having a Technology Transfer Office (TTO) to support commercialization of an invention.<\/p>\n BIC BRIDGE is based on the project main outputs and results from BiC \u2013 Biomarker Commercialization. Thanks to the regular project, the BiC consortium managed to tackle specific challenges from the biomarker development and commercialization field.<\/p>\n BIC BRIDGE serves not only to improve the outputs delivered in the original project but also to a whole new set of activities aiming at increasing the scope of the tools and broadening the target groups, as well as increasing usability, sustainability and impact, through<\/p>\n The Partnership<\/strong><\/p>\n The consortium comprises 9 partners from the Baltic Sea Region (BSR) and beyond. It consists of innovation units localized in research institutions, cluster organisations, SMEs and European Research Infrastructure Consortium within the health diagnostic, pharma and med tech field.<\/p>\n Project Partners:<\/p>\n The Funding<\/strong><\/p>\n BIC BRDIGE is based on project outputs generated during the first stage project BIC \u2013 Biomarker Commercialization. The extension stage project is running for 9 months (01.10.2020 \u2013 30.06.2021).<\/p>\n\n
\n